- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03630588
Effect of the Consumption of an Enriched Surimi in Abdominal Visceral Adiposity
Effect of the Consumption of an Enriched Surimi in Abdominal Visceral Adiposity. Randomized, Controlled, Parallel and Double-blind Study
The finding that the combination of the inactivated probiotic Bifidobacterium Lactis (BPL1), inulin as a source of soluble fiber and omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in a surimi matrix has positive effects on visceral adiposity , insulin resistance and plasma tryclycerides in a preclinical model of rats that present obesity induced by diet is the basis of the present hypothesis. This finding is based on the fact that these three bioactive compounds exert these effects through sensibly different and complementary mechanisms, which suggests that their combined use may have synergistic effects.
On this basis the present hypothesis is posed: the consumption of surimi enriched with inactivated probiotic BPL1, inulin and omega-3 fatty acids, in the same doses that have been effective in obese rats (SIAP), can induce a reduction of more than 5% of visceral adipose tissue, being clinically relevant in people with abdominal obesity.
If the effect on abdominal obesity is associated or not with a lower glycemia and / or absorption of fats induced by the consumption of surimi can be evaluated by monitoring these parameters for 4 hours after the ingestion of a breakfast high in fat.
The main objective of this study was to evaluate the effects of the consumption of surimi enriched with the probiotic BPL1, inulin and omega-3 fatty acids, on visceral abdominal adiposity in people with abdominal obesity.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Tarragona
-
Reus, Tarragona, Spain
- Centro Tecnológico de Nutrición y Salud (Eurecat-Reus)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women over 18 years of age with a waist circumference ≥102 cm in men and ≥88 cm in women.
- Sign the informed consent.
Exclusion Criteria:
- Having any condition incompatible with nuclear magnetic resonance (RNM) tests, such as metallic implants or sensitive to magnetic fields, pacemakers or suffering from claustrophobia.
- Having diabetes (glucose ≥ 126 mg / dL).
- BMI values ≥ 40 kg / m2
- Waist circumference> 150 cm.
- Present dyslipidemia (LDL cholesterol ≥ 189 mg / dL and / or triglycerides ≥ 350 mg / dL).
- Take supplements or multivitamin supplements or phytotherapeutic products that interfere with the treatment under study.
- Present chronic alcoholism.
- Present some chronic gastrointestinal disease.
- Present intolerances and / or food allergies related to the study product.
- Presenting anemia (hemoglobin ≤13 g / dL in men and ≤12 g / dL in women)
- Present some chronic disease in clinical manifestation.
- Being pregnant or intending to become pregnant.
- Be in breastfeeding period.
- Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days prior to inclusion in the study.
- Follow a hypocaloric diet and / or pharmacological treatment for weight loss.
- Suffer eating disorders.
- Being unable to follow the study guidelines.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Conventional surimi It was a 3 months nutritional intervention. Volunteers will eat 50g per day of conventional surimi. |
Experimental: Surimi intervention
|
The bioactive compounds used to obtain the surimi product are:
It was a 3 months nutritional intervention. Volunteers will eat 50g per day of enriched surimi. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in abdominal visceral fat (measured in mm2)
Time Frame: 12 weeks, week 1 and week 12
|
measured by magnetic resonance imaging (MRI), transverse body scan in one axial slice 5 cm over L5-S1.
|
12 weeks, week 1 and week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in parameters of body composition (weight, measured in kg)
Time Frame: 12 weeks, week 1 and week 12
|
Trained dieticians measure weight using a body composition analyzer (Tanita SC 330-S; Tanita Corp., Barcelona, Spain).
|
12 weeks, week 1 and week 12
|
Changes in parameters of body composition (height, measured in meters)
Time Frame: 12 weeks, week 1
|
Trained dieticians measure height using a well mounted stadiometer (Tanita Leicester Portable; Tanita Corp., Barcelona, Spain)
|
12 weeks, week 1
|
Changes in parameters of body composition (BMI)
Time Frame: 12 weeks, week 1 and week 12
|
Body mass index (BMI) is calculated as the ratio between measured weight (kg)/and the square of height (m).
|
12 weeks, week 1 and week 12
|
Changes in parameters of body composition (waist circumference, measured in centimeters)
Time Frame: 12 weeks, week 1 and week 12
|
Waist circumference (WC) is measured at the umbilicus using a 150 cm anthropometric steel measuring tape.
|
12 weeks, week 1 and week 12
|
Changes in blood pressure (measured in mmHg)
Time Frame: 12 weeks, week 1 and week 12
|
Systolic and diastolic blood pressure (SBP and DBP) are measured twice after 2-5 minutes of patient respite, seated, with one-minute interval in between, using an automatic sphygmomanometer (OMRON HEM-907; Peroxfarma, Barcelona, Spain).
|
12 weeks, week 1 and week 12
|
Changes in plasmatic parameters (glucose, total cholesterol, LDL and HDL cholesterol, triglycerides, non-esterified fatty acids, Apo B100, Apo A1 and Insulin, measured in mg/dL)
Time Frame: 12 weeks, week 1 and week 12
|
Serum lipids and apolipoproteins, non-esterified fatty acids, glucose, and insulin concentrations are measured in serum by standardized enzymatic automated methods in an autoanalyzer (Beckman Coulter-Synchron, Galway, Ireland).
LDL-c is calculated by the Friedewald formula.
|
12 weeks, week 1 and week 12
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SURINORM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity, Abdominal
-
National Research Council, SpainMinisterio de Economía y Competitividad, SpainCompletedSubjects With Abdominal ObesitySpain
-
Ben-Gurion University of the NegevUniversity of Leipzig; Harvard School of Public Health (HSPH)CompletedMen With Mild Abdominal ObesityIsrael
-
Université Catholique de LouvainCompletedAbdominal ObesityBelgium
-
Pusan National University Yangsan HospitalCompletedAbdominal ObesityKorea, Republic of
-
KU LeuvenVLIR-UOS; Kyambogo University; Our Lady of Africa Mbuya Catholic ParishCompleted
-
Assiut UniversityUnknownAbdominal ObesityEgypt
-
University of LeipzigUnknown
-
Cairo UniversityCompleted
-
Dominion Aesthetic Technologies, Inc.Completed
-
Pennington Biomedical Research CenterCompletedAbdominal ObesityUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States